Twitter - How to add to #RealisticVirtualEarth?: The Pharma.AI Platform PandaOmics (The Target Finder) Chemistry42 (The Molecule Designer) InSilicoMeds (The Trial Predictor)
How to add to #RealisticVirtualEarth?
The Pharma.AI Platform
#PandaOmics (#TargetFinder)
#Chemistry42 (#MoleculeDesigner)
#InSilicoMeds (#TrialPredictor)
https://share.google/aimode/
#RentosertibTrialDetails that #
https://share.google/aimode/
How to add to #RealisticVirtualEarth?
— WUaSPress (@WUaSPress) September 7, 2026
The https://t.co/QntiDZNTyy Platform #PandaOmics (#TargetFinder) #Chemistry42 (#MoleculeDesigner) #InSilicoMeds (#TrialPredictor)https://t.co/1WeqpsS0CI#RentosertibTrialDetails that #ReversedBiologicalAgingMarkers -https://t.co/un52onVgaD?
https://x.com/WorldUnivAndSch/
https://x.com/WUaSPress/
https://x.com/Q_YogaMacFlower/
https://x.com/sgkmacleod/
https://x.com/HarbinBook/
The Pharma.AI Platform
PandaOmics (The Target Finder)
Chemistry42 (The Molecule Designer)
InSilicoMeds (The Trial Predictor)
PandaOmics (The Target Finder)
Chemistry42 (The Molecule Designer)
InSilicoMeds (The Trial Predictor)
What are the details of the rentosertib trial that reversed biological aging markers?
* * *
insilico medicine ai drug discovery and google's founders re sergey brin and larry page
Insilico Medicine, a prominent pioneer in generative AI-driven drug discovery, and Google’s co-founders, Sergey Brin and Larry Page, are major forces driving a shared frontier: leveraging advanced computation and artificial intelligence to combat human aging and disease. [1, 2]
While Brin and Page do not directly run Insilico Medicine (which was founded and is led by CEO Dr. Alex Zhavoronkov), their ideological missions, investment circles, and corporate ecosystems are deeply intertwined in the multibillion-dollar "longevity biotech" movement. [1, 2, 3]
1. The Core Intersection: Curing Aging Through AI
Both Insilico Medicine and Google's founders view aging not as an inevitable natural law, but as a complex biological program that can be reverse-engineered using data science. [1]
- Insilico Medicine's Approach: Founded in 2014, the company pioneered using Generative Adversarial Networks (GANs) to conceptualize new molecules from scratch. It specializes in discovering treatments for age-related illnesses, such as fibrosis and oncology. Its lead AI-designed drug candidate, rentosertib (for idiopathic pulmonary fibrosis), is a primary example of how AI can shrink preclinical timelines from six years down to just a fraction of that time. [1, 2, 3, 4]
2. Overlapping Investment Ecosystems
| Entity / Investor | Connection to Insilico Medicine | Connection to Google's Founders |
|---|---|---|
| Peter Thiel | His network and major biotech co-investors heavily back Insilico. | Co-invests alongside Brin in anti-aging research and biotech platforms. |
| Vinod Khosla | Khosla Ventures funds heavily overlap in the AI/longevity space supporting Insilico. | Maintained long-term strategic dialogues with Brin and Page regarding healthcare regulations. |
| Google Cloud & Gemini | Insilico integrated Google's Gemini models and Enterprise Agent Platform into its own "PandaClaw" system to accelerate target discovery. | Brin and Page remain the controlling shareholders of Google's parent company, Alphabet, which owns these AI architectures. |
3. Competitors or Collaborators?
While Insilico Medicine operates as an independent, publicly traded biotech firm (listed on the Hong Kong Stock Exchange), Google has simultaneously built internal rivals to Insilico's business model. [1]
- Alphabet operates Isomorphic Labs (born out of Google DeepMind).
- Led by Demis Hassabis, Isomorphic Labs uses AI architectures like AlphaFold to map proteins and design drugs.
As Insilico's founder Alex Zhavoronkov notes on the challenge ahead, “Regardless of how rich you are…you cannot buy one year of life with a drug.” Rather, the realistic goal of these AI systems is to radically dial back a person's biological age and prevent the degradation of human health span [The Wall Street Journal].
If you are exploring the crossover between tech giants and biotech, tell me:
- Are you looking for a deep dive into Insilico's specific drug pipeline (like rentosertib)?
- Do you want to compare Google's Isomorphic Labs vs. Insilico Medicine's AI platform?
- Are you researching how to invest in the longevity biotech market?
*
Insilico Medicine ai drug discovery
Insilico Medicine is a leading biotechnology company that uses generative artificial intelligence (AI) to discover and develop new medicines. Traditionally, finding a new drug takes up to six years and costs millions of dollars. Insilico uses its AI systems to shrink that early-stage timeframe down to 12 to 18 months. [1, 2, 3]
The company is famous for creating the first entirely AI-discovered and AI-designed drug to reach human clinical trials. [1, 2]
The Pharma.AI PlatformInsilico operates an "end-to-end" software suite called Pharma.AI, which manages the drug creation process from A to Z. Think of it as a three-step assembly line: [1, 2]
- PandaOmics (The Target Finder): This tool acts like a biological detective. It analyzes massive amounts of data from patients to find the exact root cause of a disease—like a specific protein or "target" that needs to be blocked. [1, 2]
- Chemistry42 (The Molecule Designer): Once the target is found, this system imagines and designs brand-new chemical structures to attack it. It works like a 3D printer for molecules, inventing formulas that have never existed before. [1, 2]
- InSilicoMeds (The Trial Predictor): This tool helps predict how a drug will behave in human clinical trials, saving time and lowering the risk of failure. [1, 2]
Major Milestones & Breakthroughs- Rentosertib (ISM001-055): This is Insilico's flagship drug candidate designed to treat Idiopathic Pulmonary Fibrosis (IPF), a severe lung disease. In recent trials, the drug met its safety goals and even showed potential to reverse biological aging indicators in patients.
- Massive Pipeline: Insilico has nominated over 30 preclinical candidates for diseases ranging from cancer to immune disorders, with multiple drugs actively advancing through human clinical trials.
- Mega Partnerships: Major pharmaceutical giants, including Eli Lilly and SK Biopharmaceuticals, partner with Insilico or pay billions to license their AI-discovered molecules.
- Robotic Labs: To test its AI concepts in the real world, Insilico pairs its software with fully automated, robotic smart labs that mix and test chemicals without human error. [1, 2, 3, 4, 5, 6, 7]
Would you like to know more about how their specific drug for lung disease works, or are you more interested in the software platforms they license to other scientists?
*
What are the details of the rentosertib trial that reversed biological aging markers?
#RentosertibTrialDetails that #
Rentosertib (formerly known as ISM001-055) is an oral small-molecule drug developed by Insilico Medicine using generative AI. While popular media sometimes frames it as a "reverse-aging" pill, scientists clarify that rentosertib has not been established as an anti-aging therapy for general rejuvenation. Instead, it is an investigational drug designed to treat idiopathic pulmonary fibrosis (IPF), a severe, age-related lung disease. [1, 2, 3, 4]
The connection to biological aging comes from its unique mechanism and exploratory biomarker data collected during its clinical trials. [1, 2]
The "Aging" Connection: How it WorksRentosertib targets TNIK (Traf2- and Nck-interacting kinase). Insilico's AI platform prioritized TNIK by evaluating biological pathways where cellular senescence, chronic inflammation, and fibrosis intersect. [1, 2, 3, 4]
- Senomorphic Activity: In laboratory models, rentosertib acts as a senomorphic agent. It doesn't necessarily kill old cells (like a senolytic), but it modifies them so they stop releasing harmful, pro-inflammatory chemicals. [1, 2, 3]
- Reduction in Markers: The drug has demonstrated the ability to significantly reduce the senescence-associated secretory phenotype (SASP) and halt extracellular matrix remodeling, which are two core drivers of biological aging and organ scarring. [1, 2]
Clinical Trial Details & FindingsThe human data pointing toward these biological aging adjustments came from its Phase IIa clinical trial (GENESIS-IPF), the results of which were published in Nature Medicine. [1, 2]
- The Cohort: The trial involved 71 adult patients diagnosed with IPF. [1]
- The Design: A 12-week, randomized, double-blind, placebo-controlled study evaluating multiple dosing arms (30 mg once daily, 30 mg twice daily, 60 mg once daily, and a placebo). [1]
- Proteomic Profiling (The Aging Markers): Researchers performed deep proteomic profiling on patient serum samples, mapping 2,841 proteins using the Olink Explore panel. They observed:
- Primary Outcomes: The 60 mg once-daily dose was safe, well-tolerated, and demonstrated a significant clinical response, showing a mean improvement in lung function (Forced Vital Capacity) of +98.4 mL over 12 weeks, compared to a -20.3 mL decline in the placebo group. [1, 2]
Current Status (2026)Insilico Medicine officially initiated a global Phase III clinical trial for Rentosertib. This larger study is a randomized, double-blind, placebo-controlled trial evaluating roughly 320 patients over 52 weeks. It will use advanced AI algorithms to track whether rentosertib can safely achieve a true clinical reversal of fibrotic lung damage over a longer term. [1, 2, 3]
If you are looking into the clinical side of longevity, would you like to explore other actual cellular reprogramming trials focused purely on age-reversal, or do you want more details on the AI design process behind rentosertib?
Society, Information Technology, and the Global University, (forthcoming, Academic Press at World University and School, 2026)
Scottish Small Piping album #2 - Honey Piobaireachd (2022)
- https://twitter.com/
Scottish Small Piping album #1 Honey in the Bag ~ Out of the Air tune (2020)
Order Book #4 To the Dance or the Pools? ~ Virtually! How different it is to soak at Harbin Hot Springs, than to realize it in virtual reality (2019, Academic Press at WUaS)
Order Book #3 Winding Road Rainbow: Harbin, Wandering & the Poetry of Loving Bliss (2018, Academic Press at WUaS)
Order Actual-Virtual Ethnographic Book #1: Naked Harbin Ethnography (2016, Academic Press at World University and School)
- Scott GK MacLeod
Founder, President, CEO & Professor
at / of best STEAM CC licensed OCW, Wiki,
World University & School (WUaS)
- USPS US Post Office, PO Box 132, General Delivery, Canyon, CA 94516
1) non-profit 501(c)(3) Public Charity
building on CC-4 licensed MIT OCW in 7 languages -
https://ocw.mit.edu/ & https:/
http://
http://
2) for profit general stock company WUaS Corporation in CA - http://
- wuas_ceo@
https://wiki.
https://wiki.
https://wiki.
World University & School Innovation Research -
- http://scottmacleod.com
- https://twitter.com/
- https://x.com/Q_
- http://www.linkedin.com/in/
- https://twitter.com/
- https://scott-macleod.
- https://
* * *
#Rentosertib for IPF (https://www.nature.com/
https://share.google/aimode/
https://x.com/WorldUnivAndSch/
https://x.com/WUaSPress/
https://x.com/Q_YogaMacFlower/
https://x.com/HarbinBook/
https://x.com/sgkmacleod/
https://share.google/aimode/
#Rentosertib for IPF (https://t.co/9uYCG2Oc2E), & #ER100 for Glaucoma, in clinical trials, 2 of the most groundbreaking experimental therapies in medicine; Both drugs use #CellularRejuvenation & #AntiAgingScience to treat severe diseases w/o cure so far https://t.co/JEejKqItn5 ~
— WorldUnivandSch (@WorldUnivAndSch) September 9, 2026
https://x.com/WorldUnivAndSch/
https://x.com/WUaSPress/
https://x.com/Q_YogaMacFlower/
https://x.com/HarbinBook/
https://x.com/sgkmacleod/
https://x.com/scottmacleod/
https://x.com/TheOpenBand/
https://x.com/TheOpenBand/
*
Did Pharma.AI - https://pharma.ai/ - design Rentosertib for IPF?
Yes -
Yes, Insilico Medicine used its generative AI platform, Pharma.AI, to discover and design Rentosertib (formerly ISM001-055) specifically for idiopathic pulmonary fibrosis (IPF). [1, 2, 3]
As reported in Nature Medicine, “Our approach resulted in the first antifibrotic, small-molecule TNIK inhibitor, rentosertib (formerly ISM001-055), for the treatment of IPF designed by generative AI.”
How the AI Designed the Drug
- Target Discovery: The AI platform used data to find a new target called TNIK that causes lung scarring and aging.
- Molecule Creation: The system used generative AI to build a brand new small molecule that fits into the TNIK protein.
Clinical Progress
- Phase IIa Trials: Tests showed the drug is safe and helps improve lung function in patients.
- Phase III Studies: The treatment has moved into large-scale late-stage clinical trials.
- Read full details on the study from Nature Biotechnology.
Would you like to know more about how Phase III trials work or how AI is used to target aging?
*
Rentosertib for IPF (https://www.nature.com/
Rentosertib for IPF, and ER-100 for 2 glaucoma conditions
Rentosertib and ER-100 are two of the most groundbreaking experimental therapies in medicine. Both drugs use cellular rejuvenation and anti-aging science to treat severe diseases that currently have no cure: Idiopathic Pulmonary Fibrosis (IPF) and Glaucoma. [1, 2, 3]
While they target different parts of the body, they both represent a massive shift from just managing symptoms to actually rewinding the biological clock of damaged cells. [1]
Rentosertib for IPF (Idiopathic Pulmonary Fibrosis)Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease where the lungs become scarred and stiff, making it hard to breathe. Rentosertib (previously called ISM001-055) is an oral pill designed to stop this scarring. [1, 2, 3]
- The AI Connection: Rentosertib is famous for being the world’s first fully AI-designed drug to reach late-stage human trials. Artificial intelligence was used to discover both the biological target and the chemical structure of the drug from scratch. [1, 2, 3, 4]
- How It Works: It blocks a specific protein called TNIK, which is heavily involved in lung tissue scarring, chronic inflammation, and cell aging. [1]
- The "Age Reversal" Discovery: Data published in Nature Biotechnology shows that Rentosertib actually reversed the biological age of patients. When scientists tested patients' blood using "aging clocks" (tools that measure cellular wear and tear), those taking Rentosertib showed a noticeable reduction in biological age markers. [1, 2, 3]
- Current Status: After successful Phase IIa trials where it significantly improved lung function compared to a placebo, Rentosertib has officially entered Phase III clinical trials. [1, 2]
ER-100 for GlaucomaGlaucoma is an eye condition where pressure damages the optic nerve, killing off retinal ganglion cells (the neurons that send pictures from your eye to your brain). Once these cells die, the vision loss has historically been permanent. ER-100 aims to change that. [1]
- The Science of Rejuvenation: Co-developed by famed Harvard molecular biologist David Sinclair, ER-100 is a type of epigenetic reprogramming therapy. It is built on the concept that aging cells haven't lost their original blueprints; they just forgot how to read them due to chemical clutter (methylation) on the DNA. [1, 2]
- How It Works: A modified, harmless virus is injected directly into the eye. This virus delivers three specific genes—known as Yamanaka factors (OSK)—into the damaged eye cells. These factors wipe away the "clutter," essentially resetting the cells to a much younger, healthier state so they can repair themselves. [1, 2, 3]
- The Safety Switch: To keep the cells from rolling back too far (which could cause tumors), the treatment is only active when the patient takes a common antibiotic called doxycycline. Doctors can turn the therapy on and off simply by controlling the antibiotic intake. [1]
- Current Status: ER-100 is the first-ever cellular rejuvenation therapy of its kind cleared by the FDA for human testing. It is currently in a Phase 1 clinical trial with human patients to test its safety and see if it can successfully restore lost vision. [1, 2]
Summary Comparison| Feature | Rentosertib | ER-100 |
|---|---|---|
| Primary Target Disease | Idiopathic Pulmonary Fibrosis (IPF) | Open-Angle Glaucoma & NAION |
| How It is Taken | Oral pill (by mouth) | Intravitreal injection (into the eye) |
| Core Technology | Generative AI & TNIK inhibition | Epigenetic reprogramming (OSK genes) |
| Anti-Aging Effect | Lowers systemic biological age markers | Rewinds optic nerve cells to a youthful state |
| Current Clinical Phase | Phase III (Large-scale efficacy testing) | Phase I (Initial human safety testing) |
| Developer | Insilico Medicine | Life Biosciences |
Please note that both of these treatments are highly experimental and are not yet available to the general public outside of controlled clinical trials. [1, 2]
Are you looking into these therapies for a specific medical condition, or are you researching them for their longevity and anti-aging properties? Let me know so I can give you more targeted information or help you look up active clinical trial registries!
* * *
Automatic reply: A - Tu 9/8/26 & M 9/14/26 open best STEAM Creative Commons' licensed OpenCourseWare wiki World Univ & Sch WUaS News and Q&A, with Zoom URL ~ moving forward further into Canyon 94516 soon, that even WUaS's labors in growing a worldwide abolition movement - & with abolishing or knocking back international organized crime as a rubric, or i.o.c. as a heuristic, and in developing free WUaS universities in all 200 countries
Dear Ma, Pin, Ed, Peter, Byron, Nancy, Alden, Sandy, all,
On this Labor Day, this auto response from Contra Costa county's Melissa Hickok, Assistant to Kristin B. Connelly, County Clerk-Recorder and Registrar of Voters, last night gives me some hope that I might be moving forward further into Canyon 94516 soon, that even WUaS's labors in growing a worldwide abolition movement - & with abolishing or knocking back international organized crime as a rubric, or i.o.c. as a heuristic, and in developing free WUaS universities in all 200 countries - may be paying off -
| Sun, Sep 6, 10:03 PM (12 hours ago) | |||
| ||||
Thoughts?
Just headed on to Limantour beach in Pt Reyes for a swimmers' shower and hour long walk.
Might I and the WUaS Academic Medical Center have moved into 670 Ridgecrest Rd, Canyon 94516 by the end of this week?
Happy Labor Day! Yogically, Warm regards,
Scott
*
https://baynature.org/magazine/summer2012/point-reyes-on-the-edge/
https://en.wikipedia.org/wiki/Pisaster_ochraceus
https://commons.wikimedia.org/wiki/Category:Pisaster_ochraceus
....
Posts
